Enhanced Targeting and Immune Activation of Tumor Microenvironment by Nanomodified Anti-PD1 in Liver Cancer
Date
2021
Authors
Ou, D.L.
Tseng, S.J.
Kempson, I.M.
Hsu, C.L.
Yang, P.C.
Liao, Z.X.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Advanced Therapeutics, 2021; 4(6)
Statement of Responsibility
Conference Name
Abstract
Liver cancer is one of the most common cancers worldwide, 75% of which are hepatocellular carcinoma (HCC). Generally, chronic inflammation and animmunosuppressive tumor micro environment are steadily activated in HCC. Although the US Food and Drug Administration (FDA) has approved immune checkpoint inhibitors (ICIs) for use as a clinically advanced HCC treatment,their efficacy in the clinical setting is not satisfactory. Moreover, only a small fraction of antibody reaches the target via systemic circulation due to neutralization of antibodies and off-target delivery. To enhance the localized effects of ICIs, iron oxide nanoparticles (≈10 nm) are conjugated with an antiprogrammed death-1 (anti-PD1) antibody and introduced the ironized antibodies into orthotopic HCC tumors via the systemic circulation. When mice are sacrificed 13 days after the final treatment, mice treated with ironizedanti-PD1 significantly regulate tumor-infiltrating leukocytes (TILs), particularly amplifying T-cell functions and recruiting M1 macrophages. More importantly,biochemical indices indicate that mice treated with ironized anti-PD1 recover liver function. This work presents iron oxide nanoparticles integrated with an anti-PD1 antibody that immunomodulates the immunosuppressive tumor micro environment to generate synergistic effects that achieve tumor inhibition and immune response activation in the context of HCC therapy.
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supporting Information, https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fadtp.202100048&file=adtp202100048-sup-0001-SuppMat.pdf
Access Status
Rights
Copyright 2021 Wiley